Journal Article Summary
The article examines the long-term effects of ticagrelor, a medication used to prevent blood clots, in patients who have previously undergone coronary stenting following a heart attack. This topic is significant because patients with a history of coronary stenting are at a heightened risk for serious cardiovascular events, such as heart attacks and strokes. Understanding the efficacy and safety of extended ticagrelor therapy could help improve treatment strategies for these high-risk patients.
In the study, researchers analyzed data from the PEGASUS-TIMI 54 trial, which included over 21,000 patients, with about 80% having prior coronary stenting. Participants were randomly assigned to receive either ticagrelor (at doses of 60 mg or 90 mg twice daily) or a placebo, alongside low-dose aspirin. The findings indicated that ticagrelor significantly reduced the occurrence of major adverse cardiovascular events, such as heart attacks and strokes, compared to placebo, with a reduction in such events observed regardless of the type of stent used. However, the use of ticagrelor was also associated with an increased risk of major bleeding.
Despite the promising results, the study has limitations, including the non-randomized nature of prior stenting and the lack of detailed data on the stenting procedures. Patients should discuss the findings with their healthcare professionals, especially considering the increased risk of bleeding associated with ticagrelor. It is essential for patients to weigh the benefits of reduced cardiovascular events against the potential risks when considering long-term antiplatelet therapy.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Bergmark Brian A., Bhatt Deepak L., Steg P. Gabriel, Budaj Andrzej, Storey Robert F., Gurmu Yared, Kuder Julia F., Im KyungAh, et al.. Long‐Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS‐TIMI 54 Trial. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease 2021. DOI: 10.1161/JAHA.120.020446. PMID: 34423649. PMCID: PMC8649257.
Featured Pill Pals Product
OTC 1000 (1,000) Count Low Dose Aspirin 81mg for Adults and Children 12 years and over --- Generic For Bayer Low Dose --- Time Cap Labs
1000 (1,000) Count Low Dose Aspirin 81mg for Adults and Children 12 years and over --- Generic For Bayer Low Dose --- Time Cap Labs is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. No prescription required for eligible over-the-counter purchases.
